Related Experiment Video
Updated: Aug 13, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
[Interstitial lung disease in mixed connective tissue disease]
Judit Végh1, Mária Szilasi, Györgyike Soós
1Debreceni Egyetem, Orvos- es Egészségtudományi Centrum, Altalános Orvosi Kar, III. Belgyógyászati Klinika, Immunológiai Tanszék.
Orvosi Hetilap
|January 18, 2006
Summary
More than half of mixed connective tissue disease patients develop interstitial lung disease, often within 2-4 years. Early diagnosis via CT scans and treatment with corticosteroids and cyclophosphamide are crucial for managing this condition.
Area of Science:
- Rheumatology
- Pulmonology
- Internal Medicine
Background:
- Mixed connective tissue disease (MCTD) can present with significant pulmonary complications.
- Interstitial lung disease (ILD) is a common and potentially severe manifestation in MCTD patients.
- Understanding the natural history and therapeutic options for ILD in MCTD is critical.
Purpose of the Study:
- To analyze the incidence and pathological course of interstitial lung disease in patients with mixed connective tissue disease.
- To evaluate the effectiveness of current therapeutic strategies for interstitial lung disease in MCTD.
- To investigate the co-occurrence and management of pulmonary arterial hypertension in MCTD-associated ILD.
Main Methods:
- A longitudinal study followed 179 patients with MCTD for an average of 15.9 years.
- High-resolution computed tomography (HRCT) was the primary diagnostic tool for interstitial lung disease.
- Open lung biopsy was performed in select cases to confirm diagnosis; respiratory function tests were also utilized.
Main Results:
- Interstitial lung disease was diagnosed in 53.6% of the 179 MCTD patients, with onset most frequent between 2-4 years.
- Severe pulmonary fibrosis developed in 25% of patients within four years of ILD onset.
- Combination therapy of corticosteroids and cyclophosphamide was required for 51 patients; pulmonary arterial hypertension was identified in 4 patients and successfully managed.
Conclusions:
- Pulmonary involvement, particularly interstitial lung disease, is highly prevalent in MCTD.
- Early detection of ILD is feasible using computed tomography, enabling timely intervention.
- Combined corticosteroid and cyclophosphamide therapy shows efficacy in managing MCTD-associated ILD, and the co-existence with pulmonary arterial hypertension was noted and managed.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.